Opendata, web and dolomites

Light4Sight SIGNED

Light-activated carriers for the controlled delivery of therapeutic peptides in posterior segment eye diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Light4Sight project word cloud

Explore the words cloud of the Light4Sight project. It provides you a very rough idea of what is the project "Light4Sight" about.

healthcare    reduces    toxicity    administration       aged    sales    irradiation    intraocular    injected    provides    doses    biopharmaceutical    complete    half    frequent    activated    burden    macular    ing    invasive    drugs    diseases    concentration    quality    patients    light    benefits    assembling    treat    treatment    chronic    glaucoma    peptides    loading    adverse    avoiding    diabetic    life    nanocarriers    protein    ways    intravitreal    retinopathy    2016    repeated    sensitive    light4sight    global    exceeded    consequently    clearance    suspended    barriers    injections    vitreoretinal    rapid    ocular    innovative    2025    posterior    visible    injection    suffering    acceptable    systemic    platform    providers    biopharmaceuticals    treatments    match    lifestyle    supramolecular    primarily    self    incorporating    vitreous    topical    vision    dose    risk    minimizes    moderate    burst    hydrogel    release    eye    site    evades    reducing    peptide    35    population    billion    drug    alternative    protects    pose    therapeutic    consisting    degeneration    placing    ophthalmic    market    demand    age    patient    therapy   

Project "Light4Sight" data sheet

The following table provides information about the project.

Coordinator
QUEEN MARY UNIVERSITY OF LONDON 

Organization address
address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS
website: http://www.qmul.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) coordinator 224˙933.00

Map

 Project objective

In 2016, the global sales of biopharmaceutical drugs (protein, peptides) in ophthalmic applications exceeded $8 billion and is estimated to increase to $35.7 billion by 2025. The growth of the ophthalmic drug market is primarily driven by an increasing aged population suffering from age- and lifestyle-related diseases such as macular degeneration, diabetic retinopathy, glaucoma, among others. These diseases cause moderate or complete vision loss, resulting in significant reduction in quality of life. Consequently, innovative approaches for the effective delivery of biopharmaceuticals for the treatment of chronic intraocular diseases are required. Currently, intravitreal injection of drugs is the most acceptable and effective method to treat vitreoretinal diseases. By placing the drug in the posterior eye, it evades the ocular barriers common in topical and systemic delivery, allowing higher drug doses to reach the target site. However, treatments require frequent injections to maintain adequate intraocular concentration, which are invasive, increase the risk of adverse effects and pose significant treatment burden on patients and healthcare providers. Thus, alternative ways to deliver these drugs that require less frequent administration need to be developed. Light4Sight aims to develop a novel delivery platform consisting of self-assembling nanocarriers incorporating therapeutic peptides and suspended within a light-sensitive supramolecular hydrogel. The hydrogel can be injected in the vitreous and release of nanocarriers be activated through the irradiation of visible light. This approach provides several benefits: 1) minimizes the use of repeated injections reducing treatment burden; 2) reduces burst release of the nanocarriers avoiding potential dose related toxicity; 3) on-demand release to match patient needs; 4) allows high drug loading for long-term therapy; 5) protects peptide drugs from rapid clearance in the vitreous increasing their half-life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIGHT4SIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIGHT4SIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

eXcape3D (2019)

Functional dissection of X-linked regulatory DNA: unravelling the impact of genome topology on transcriptional regulation

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More  

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More